Wells Fargo

Wells Fargo’s Silence Therapeutics SLN Stock Holding History

Wells Fargo’s Portfolio SLN Stock Details SLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-19	Closed	-$131	–	7240
2024 Q4	$131	Hold	19	–	–	﹤0.01%	6397
2024 Q3	$345	Buy	+19	New	+$353	﹤0.01%	6194

Other funds holding SLN

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return

Wells Fargo's SLN Position: Q1 2025 in Review

Wells Fargo sold out of Silence Therapeutics (SLN) in Q1 2025, closing a stake of 19 shares — an estimated $131 sold.

Wells Fargo first reported a position in SLN in Q3 2024 and held it in 2 quarters. The position peaked at $345 in Q3 2024. 59 funds tracked by Wall St. Rank hold SLN as of Q1 2025.

Wells Fargo reported no remaining Silence Therapeutics position as of Q1 2025 after selling out during the quarter.
Wells Fargo sold 19 Silence Therapeutics shares in Q1 2025, an estimated $131.
Wells Fargo first reported a position in Silence Therapeutics in Q3 2024 and held it in 2 quarters.
Wells Fargo's Silence Therapeutics position peaked at $345 in Q3 2024.
59 funds tracked by Wall St. Rank held Silence Therapeutics as of Q1 2025.

Based on Wells Fargo's 13F filing for Q1 2025, filed 13 May 2025.